REPORT HIGHLIGHTS
-
In 2003, the combined worldwide market for cardiac markers, drugeluting stents, portable automated external defibrillators, and cardiac resynchronization therapy was estimated at $4.46 billion.
-
These four areas, plus angiogenesis/gene therapy products introduced during the forecast period, are expected to rise at an average annual growth rate (AAGR) of 29% to nearly $16 billion in 2008.
-
The first four product categories represent segments in which dramatic change is underway. All of these areas will experience double digit growth throughout the forecast period.
-
Angiogenesis-stimulating therapies and gene therapies represent the next revolution in this area of healthcare, with approval of the first product, an angiogenesis-stimulating agent, possible before the end of 2004.
SUMMARY FIGURE
PERCENT OF THE MARKET HELD BY SELECTED CUTTING-EDGE CARDIOVASCULAR THERAPIES: WORLDWIDE, 2003 AND 2008
(%)
Source: BCC, Inc.
REPORT SCOPE
INTRODUCTION
Cardiovascular disease comprises conditions that affect the proper functioning of the heart and blood vessels. Among the most prevalent of life-threatening diseases are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die of cardiovascular disease, particularly AMIs and strokes.
Cardiovascular disease remains the leading cause of death in developed countries. In the U.S., one person dies every 30 seconds from heart disease. This translates to more than 2,600 people a day. Each year in the U.S., deaths from cardiovascular disease represent approximately 42% of all deaths, or some one million deaths. Heart diseaseis the leading cause of death for all Americans age 35 and older.
This BCC report provides an in-depth assessment of new product introductions in several categories of cardiovascular medicine that are revolutionizing not only diagnosis and treatment of certain cardiovascular disorders, but their markets as well. These products include cardiac markers for the detection of AMI and CHF, drug-eluting stents to prevent restenosis following percutaneous transluminal coronary angioplasty, automated external defibrillators to treat patients suffering from sudden cardiac arrest and cardiac resynchronization therapy for the treatment of CHF.
Also discussed in this report are advances in angiogenesis stimulation to treat angina, coronary artery disease and peripheral vascular disease, as well as gene therapy approaches to several cardiovascular disorders.
SCOPE OF STUDY
The report contains:
- A comprehensive overview of one category of diagnostics, one category of therapeutics and three categories of devices that are, or will be revolutionizing the treatment of cardiovascular diseases
- A chapter on each of the five categories: cardiac markers, drug-eluting stents, automated exexternal defibrillators, cardiac resynchronization therapy and angiogenesis/gene therapy
- Full descriptions of the technologies involved and how these differ from existing and emerging technologies
- Analysis of the technological approaches undertaken by the various competitors and industry and end-user response to these products
- Regulatory issues and legislation affecting use and marketing of products
- Market forecasts for each category of product through 2008, and profiles of selected competitors in each category are included.
METHODOLOGY
The base year for this study is 2003. Market figures are based on revenues at the manufacturers' level and are projected at 2004-dollar value (i.e., inflation is not computed into the projection figures).
INFORMATION SOURCES
Data to prepare this study was derived from information obtained from interviews with management at companies competing or which have products in development that will compete in the five categories covered in the report. In addition, interviews were conducted with physicians and other professionals working in cardiovascular treatment centers to gain insight into clinical assessment and usage of and preference for different therapeutics and devices, and with laboratory personnel to gain insight into usage of diagnostics. Key information from literature was used to obtain expert opinions on commercial potential and market sizes from industry professionals.
AUTHOR'S CREDENTIALS
Lynn Gray has been a research analyst in biotechnology and life sciences since 1989 and with BCC since 1996. During that time, she has authored numerous reports in the biomedical field, 20 for BCC alone. BA, University of California, Riverside, 1973.
